It had $22.7 billion of cash on its balance sheet at the end of June. On the date of publication, Dana Blankenhorn did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. These stocks might bounce around with the rest of the stock market, but you can count on these companies to deliver dividend payments to your account that grow every year. Pfizer’s current guidance is that 2020 free cash flow will come to $10 billion to $11 billion, cutting the dividend and indicating a yield of 3.6%. Pfizer’s best-known drug right now is Xeljanz, an immunosuppressant (called a JAK inhibitor) for which it now has four indications, including arthritis. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. In the first half of 2020, the company returned $1.5 billion in the form of share repurchases and another $1.9 billion in the form of quarterly dividend payments. All rights reserved. Johnson & Johnson's vaccine candidate Ad26COV2.S uses a non-replicating virus to deliver genetic material human cells use to produce copies of the spike protein the novel coronavirus relies on. 2020 InvestorPlace Media, LLC. See upcoming ex-dividends and access Dividata's ratings for Pfizer Inc. PFE's next quarterly dividend payment will be made to shareholders of record on Tuesday, December 1. What makes Pfizer interesting lies beyond COVID, including work on other vaccines, on immunology, and on rare diseases. Copyright © 2020 InvestorPlace Media, LLC. Success for the vaccine candidates that Pfizer and Johnson & Johnson are developing could send these pharma stocks sharply higher overnight, but that's now why dividend investors find them attractive. Investors have paid huge premiums on sales for even the promise of a novel coronavirus treatment or vaccine. But board members like former FDA Commissioner Scott Gottlieb and investment banker Ronald Blaylock have been buying Pfizer lately. Despite increasing its payout at a blazing pace, Amgen was able to make payments over the past 12 months using just 35% of the free cash flow its operations generated over the same time frame. PFE Ex-Dividend Date 2020 November 5. The Man Who Recommended 23 1,000% Winners Is Revealing His #1 Stock for 2020. Amgen has raised its payout 103% higher over the past five years, and shareholders can reasonably expect more big dividend bumps ahead. The company also has cash. All rights reserved. Blame a long history of underperformance, the efforts to improve that performance, and a preference for more speculative issues. Board of Directors approves quarterly cash dividend of $0.38 per share The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020. All three have a proven track record for delivering profits that grow over time. Investors should understand this transaction for three reasons. This should spur our immune systems to produce antibodies that prevent real copies of the virus responsible for COVID-19 from conducting business as usual. Amgen's product lineup sports drugs with blockbuster sales right now, and more new therapies rolling through the pipeline could allow the company to keep raising its payout for years to come. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions. The current TTM dividend payout for Pfizer (PFE) as of October 08, 2020 is. In addition to the vaccine, Pfizer has begun Phase 1 studies of a treatment for Covid-19, an antiviral that will combine with Remdesivir from Gilead Sciences (NASDAQ:GILD), which Trump has been taking. Soaring sales of blood cancer drugs like Darzalex and Imbruvica helped pharmaceutical sales rise 5% year over year to $11.4 billion and more new drugs coming through the pipeline will continue moving the needle. Cumulative Growth of a $10,000 Investment in Stock Advisor, Got $500? While the market will be worth billions, the price is likely to be controlled by governments. Analysts say the combination, along with Moderna (NASDAQ:MRNA), are leading the race. PFE dividend history, yield, payout ratio, and stock fundamentals. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. Xeljanz has the second-largest ad budget in the industry, recording sales of $2.24 billion last year. See you at the top! Are you looking for stocks that can deliver steadily growing streams of income? Bourla says his company is “moving at the speed of science.” He has acted as a public face for the effort, seeking to assure consumers the result will be something safe and effective. You’ll get the name & ticker of Matt McCall’s top pick when you tune in to his FREE event. Cory is a long-term minded analyst focused on the Healthcare Sector. Returns as of 10/16/2020. PFE Dividend Yield 4.13% PFE Annual Dividend $1.52 . While delayed surgical procedures pressured the company's medical device segment, higher than expected pharmaceutical sales pushed adjusted earnings 3.8% higher year over year to $2.20 per share. You can still buy PFE stock at a reasonable price. All three of these large and diverse drugmakers have what it take to deliver market-beating gains, just remember to be patient if your new dividend-paying pharma stock hits a snag. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. The timing all depends on how soon data monitors see a predetermined number of volunteers test positive for COVID-19. In stark contrast to risky start-ups that the word biotechnology brings to mind, Amgen produces a steadily growing profit from sales of branded therapies. The pandemic forced a delay in that spinoff, so if you’re an income investor you can still get in by buying Pfizer. Amgen isn't at all shy about distributing the profit it produces with its shareholders. Pfizer is the manufacturing partner, with what CEO Albert Bourla, a veterinarian by training, calls an “open checkbook.” Even before Phase 3 trials are done, the company has produced hundreds of thousands of doses of the BioNTech vaccine. Stock Advisor launched in February of 2002. This big pharma is in the middle of a megamerger expected to complete before the end of the year that involves its post-market exclusivity product segment UpJohn, and Mylan (NASDAQ:MYL). Nasdaq Source: Manuel Esteban / Shutterstock.com, Pfizer Is a Value Play in the Covid-19 Frenzy, 7 Innovative Stocks Pushing Our World Ahead, 3 Reasons to Inject Your Portfolio with Sorrento Therapeutics, Matt McCall and the InvestorPlace Research Staff, Buy Piedmont Lithium Stock Now for Unique EV Exposure, Louis Navellier and the InvestorPlace Research Staff, Trump vs. Biden: Stocks to Buy No Matter Who Wins the White House, 7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote, 7 Value Stocks To Buy Today For Security And Consistency, Despite Its Huge Run-Up, Hyliion Stock is Still a Long-Term Buy, 7 Big Tech Stocks to Buy for Blockchain and Crypto Exposure, Exxon Mobil Stock Is Still a Buy and for the Right Reasons. The company recently told analysts it has three more vaccines in development, whose sales could equal that figure by the end of the decade.